Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer (Q37236419)

19 August 2017

1 reference

title

Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer (English)

1 reference

19 August 2017

Meghana Trivedi

1

1 reference

19 August 2017

Imawati Budihardjo

2

1 reference

19 August 2017

Kirsten Loureiro

3

1 reference

19 August 2017

Tony R Reid

4

1 reference

19 August 2017

Joseph D Ma

5

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 August 2008

1 reference

19 August 2017

1 reference

19 August 2017

4

1 reference

19 August 2017

4

1 reference

19 August 2017

483-500

1 reference

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs

19 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Recent developments in the chemistry, biology and medicine of the epothilones

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Epothilones: mechanism of action and biologic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Targeting the microtubules in breast cancer beyond taxanes: the epothilones

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Epothilones in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

A common pharmacophore for cytotoxic natural products that stabilize microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

The biology and medicinal chemistry of epothilones

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Apoptotic pathways of epothilone BMS 310705

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Synthesis of epothilones A and B in solid and solution phase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Total synthesis of epothilone B, epothilone D, and cis- and trans-9,10-dehydroepothilone D.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Nanomolar concentrations of epothilone D inhibit the proliferation of glioma cells and severely affect their tubulin cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Subcellular distribution of epothilones in human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, fludelone, via parenteral or oral route

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Do beta-tubulin mutations have a role in resistance to chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.483

Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.49.560

Identifiers

DOI

10.2217/14796694.4.4.483

1 reference

release_3cr77ogx7jb6hjakelrixye7qa

19 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3cr77ogx7jb6hjakelrixye7qa

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference